Highly rated in
Highly rated in
Check Dr. Angela A. Dispenzieri's experience treating your condition:
About Dr. Angela A. Dispenzieri

Angela Dispenzieri is a Hematologist and a Hematologist Oncology expert in Rochester, Minnesota. Dispenzieri has been practicing medicine for over 31 years and is highly rated in 29 conditions, according to our data. Her top areas of expertise are Primary Amyloidosis, POEMS Syndrome, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Minnesota. Dispenzieri is currently accepting new patients.

Her clinical research consists of co-authoring 743 peer reviewed articles and participating in 8 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Angela A. Dispenzieri it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Angela A. Dispenzieri accepts the following insurance:

  •  Ambetter
  •  Medica

Call to see if your plan is accepted.
200 1st St Sw, Rochester, MN 55905
Background & Education
Graduate Institution
Albert Einstein College Of Medicine Of Yeshiva University, 1991
Hematology Oncology
Internal Medicine in MN
Hospital Affiliations
Mayo Clinic Hospital - Saint Marys Campus
Franklin General Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Study of PS-341 for Patients With High-Risk, Newly Diagnosed Multiple Myeloma
Phase I Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL)
Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome
A Phase II Study of Flavopiridol in Patients With Relapsed and Refractory Multiple Myeloma
Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis: Protocol for a Pragmatic Cluster Randomized Clinical Trial (PREDICT-AMY)
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis
View 7 Less Clinical Trials -

743 Total Publications

Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors